ARTICLE

Volume 10,Issue 3

Cite this article
11
Citations
68
Views
26 September 2025

Effect Observation of Combination Therapy with Veglitin Tablets and Metformin Hydrochloride for Patients with Type 2 Diabetic Nephropathy

Yinyin Chen1 Jiawei Zhang*
Show Less
1 Department of Geratology and Special Hospital Ward, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China
JMDS 2025 , 10(3), 76–79; https://doi.org/10.18063/JMDS.v10i3.657
© 2025 by the Author. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

This study analyzed the efficacy of the combination therapy of Veglitinide Tablets and Metformin Hydrochloride Tablets in treating type 2 diabetic nephropathy. A total of 80 patients admitted to our hospital between January 2024 and January 2025 were enrolled. Using a randomized block design, the patients were divided into two groups for prospective analysis. The control group received Metformin Hydrochloride Tablets, while the observation group received the combined therapy of Veglitinide Tablets and Metformin Hydrochloride Tablets. The improvements in blood glucose levels and renal function were compared between the groups. Post-treatment analysis showed that the observation group exhibited lower fasting blood glucose and 2-hour postprandial glucose levels (P<0.05), with significantly reduced serum creatinine and blood urea nitrogen levels (P<0.05). The combined therapy demonstrated significant therapeutic effects in type 2 diabetic nephropathy patients, effectively regulating both blood glucose and renal function.

Keywords
Veglitin tablets
Metformin hydrochloride tablets
Type 2 diabetic nephropathy
Funding
This study is supported by S&T Program of Baoding (Project No.: 2441ZF277).
References

[1] Deng L P, Wu H M, Yuan W W, 2022, Efficacy and safety of Viglitinide and Metformin combination with Daglirenet in treating newly diagnosed type 2 diabetes mellitus patients. Chinese Journal of Diabetes, 30(2):116-119.

[2] Zhou B, Li J, Fang C Y, 2023, Comparison of clinical efficacy of Metformin/Weiglitin and Liraglutide in obese patients with type 2 diabetes mellitus. Journal of Southern Medical University, 43(3):436-442.

[3] Zhang X J, Zhang J, Lou P P, 2022, Efficacy of Veglitinib combined with Metformin in the Treatment of First-Visit Patients with Type 2 Diabetes Mellitus and Abdominal Obesity and Its Effects on Serum Kisspeptin. Drug Evaluation Research, 45(7):1355-1360.

[4] Cui X Y, 2022, Observation on the efficacy of dapagliflozin combined with metformin in treating type 2 diabetic nephropathy. Journal of Xinxiang Medical University, 39(4):362-366.

[5] Cao Y J, Zhang Z, Li X F, 2022, The effect of Veglitinide-assisted metformin treatment on glucose control and pancreatic β-cell function in newly diagnosed type 2 diabetes patients. Right River Medical Journal, 50(1):62-66.

[6] Zhang T R, You X H, Pan J G, 2021, Clinical effects of Veglitinib combined with metformin in the treatment of type 2 diabetes mellitus and analysis of its effects on FPG, INS, and 2hPG levels. Chinese Community Physician, 37(9):77-78.

Share
Back to top